Castle Biosciences, Inc.
CSTL
$18.63
-$0.41-2.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 43.82% | -124.32% | -122.08% | -49.29% | -920.05% |
| Total Depreciation and Amortization | -59.34% | -34.52% | -559.87% | 1.97% | 189.34% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -74.38% | 63.97% | 66.62% | -55.45% | 173.68% |
| Change in Net Operating Assets | 5.02% | 604.44% | 1,382.35% | 345.08% | -8.43% |
| Cash from Operations | -266.62% | 10.53% | -3.03% | -13.24% | 11.69% |
| Capital Expenditure | -162.76% | 5.06% | -132.58% | -77.15% | 48.21% |
| Sale of Property, Plant, and Equipment | -22.22% | -28.57% | 375.00% | 500.00% | 80.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 24.55% | 20.11% | 57.53% | 97.52% | -67.71% |
| Cash from Investing | -15.03% | 53.05% | -24.34% | -32.50% | -13.86% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 7.69% | -3.85% | -29.17% | -181.82% | 27.78% |
| Issuance of Common Stock | 60.83% | 175.10% | -86.22% | -20.51% | -14.38% |
| Repurchase of Common Stock | -162.35% | -15.50% | 8.42% | 4.23% | -430.59% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -224.08% | 14.78% | -209.67% | 140.48% | -114.59% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -76.43% | 25.95% | -64.60% | -384.25% | -88.90% |